Invirsa develops INV-102, a molecule that enhances ocular DNA repair and boosts the innate immune response to infections and injuries, particularly in cases of sulfur mustard gas exposure and acute infectious keratoconjunctivitis. This treatment aims to improve cellular stability and promote effective recovery, addressing the significant risk of permanent vision damage and the lack of approved therapies for viral conjunctivitis.
Funding
$7.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFounders
Product
Problem
Exposure to sulfur mustard gas causes significant DNA damage to the eyes, often leading to permanent vision impairment. Acute infectious keratoconjunctivitis, with millions of cases annually, frequently results in the over-prescription of antibiotics due to the lack of effective treatments for viral infections.
Solution
Invirsa is developing INV-102, a molecule designed to enhance ocular DNA repair and bolster the body's innate immune response to infections and injuries. INV-102 aims to improve cellular stability, facilitating more complete DNA repair and better recovery from ocular injuries caused by sulfur mustard gas. The treatment is also being developed as an effective solution for both viral and bacterial acute infectious keratoconjunctivitis, addressing the unmet need for approved therapies for viral cases. The goal is to have INV-102 readily available nationwide.
Target Audience
The primary target audience includes individuals at risk of ocular injury from sulfur mustard gas exposure, as well as patients suffering from acute infectious keratoconjunctivitis.
Features
- INV-102 augments the body’s response to DNA damage, improving cell stability.
- Designed to treat ocular injuries resulting from sulfur mustard gas exposure.
- Being developed as a treatment for acute infectious keratoconjunctivitis (both viral and bacterial).